Abstract. In previous work, it was demonstrated that apoptosis occurs in the kidney during LPS-induced acute renal failure (ARF). However, the relative importance of apoptosis in LPSinduced ARF remained unproven. Because the caspase enzyme cascade is responsible for carrying out apoptosis, it was hypothesized that treatment with a caspase inhibitor would protect mice from LPS-induced ARF. C57BL/6 mice received an injection of LPS and were treated with either the broad-spectrum caspase inhibitor z-VAD-fmk or vehicle and compared with unmanipulated mice. LPS induced a significant increase in caspase-3 activity in vehicle-treated mice, which was significantly inhibited by z-VAD. Mice that were treated with z-VAD were protected from ARF and demonstrated significantly less apoptosis as measured by both terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining and DNA laddering.
cantly less apoptosis as measured by both terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining and DNA laddering. Although apoptosis is classically described as a noninflammatory process, z-VAD treatment significantly attenuated multiple markers of inflammation, such as renal neutrophil infiltration and renal expression of the neutrophil chemotactic factor macrophage inflammatory protein-2. Thus, caspase inhibition may protect against LPS-induced ARF not only by preventing apoptotic cell death but also by inhibiting inflammation. These data raise the possibility that apoptotic kidney cells may actually be a source of this local inflammation, contributing to subsequent nonapoptotic renal injury.
Acute renal failure (ARF) is a frequent complication of sepsis, contributing substantially to the high morbidity and mortality seen in this syndrome (1, 2) . We previously described a model of sepsis in which a single injection of LPS leads to ARF (3), with little to no hemodynamic effects (4) . Despite severe functional impairment, evident by an extreme elevation in blood urea nitrogen (BUN), we observed relatively modest tubular injury, with little true necrosis. This stands in stark contrast to the widespread tubular necrosis seen in the ischemia-reperfusion model of ARF (5) .
One possible explanation for this dissociation between severe renal dysfunction and relatively intact renal structure is apoptotic cell death within the kidney, which is difficult to appreciate on routine histologic sections. Apoptosis can be initiated through either the mitochondrial pathway, which is triggered by a variety of stressors such as hypoxia or oxidative stress (6, 7) , or through the receptor-mediated pathway, which is triggered by the binding of TNF and FasL to their respective receptors (8) . Consistent with this hypothesis, LPS is known to cause an acute increase in circulating TNF (9 -11) , an upregulation in renal Fas and Fas-ligand expression (12, 13) , and an increase in markers of oxidative stress (14) . Among the multiple mediators of the complex process of apoptosis, the caspase enzyme cascade plays a central role (15) . Caspases are cysteine proteases that exist as inactive zymogens. The mitochondrial and receptor-mediated pathways of apoptosis result in activation of "initiator" caspases-9 and -8, respectively. In a cascade-like manner, these caspases activate other target caspases by cleaving away prodomains following specific aspartate-containing sequences. These two pathways ultimately intersect to activate "effector" caspases such as caspase-3, which cleave multiple structural molecules, resulting in the morphologic changes that define apoptosis.
In support of a causative role for apoptosis in LPS-induced ARF, we observed apoptosis occurring in the kidney 6 h after LPS administration and persisting for at least 48 h (3). In comparison with wild-type mice, mice that were deficient in TNFR1 exhibited markedly less renal apoptosis and significantly less ARF in response to LPS, suggesting that TNF signaling through TNFR1 was responsible for LPS-induced apoptosis, leading to ARF. However, this association does not prove that this renal apoptosis is responsible for the ARF that occurs after LPS administration, and data exist to support alternative mechanisms, such as LPS-induced neutrophilic infiltration (16, 17) . Therefore, to define further the mechanistic importance of apoptosis in this model, we examined the effect of pharmacologic caspase inhibition on LPS-induced ARF.
Materials and Methods

ARF Model
Male C57BL/6 mice were obtained commercially and studied at 9 wk of age (Charles River Laboratories, Boston, MA). Mice received a single intraperitoneally injection of 0.3 mg of Escherichia coli LPS (Sigma, St. Louis, MO) at time 0. Mice were given either z-VAD-fmk (0.24 mg in 1% DMSO; n ϭ 8) or vehicle (n ϭ 7) as a series of three intraperitoneal injections given at Ϫ30 min, 2 h, and 6 h relative to LPS injection. Preliminary experiments showed that DMSO itself has a somewhat protective effect against LPS-induced ARF, as has been observed in models of LPS-mediated liver dysfunction (18) . Therefore, the dose of LPS was increased approximately twofold in comparison with previous studies to produce ARF reliably without mortality. Blood was obtained for BUN and cytokine measurements at time 0, 2 h, and 6 h after LPS injection. Mice were killed 24 h after LPS injection, with harvest of blood and kidney tissue. BUN and creatinine concentrations were determined with a Beckman CX5CE autoanalyzer. All experiments were done in accordance with institutional animal care guidelines.
Pathology
For routine histologic analysis, kidneys were sectioned coronally, fixed in phosphate-buffered formalin, embedded in paraffin, and stained with periodic acid-Schiff base. Histologic sections for each animal were assigned a semiquantitative score for tubular injury as described by Nomura (3). A blinded observer assigned a score that ranged from 0 (no injury) to 3 (severe/widespread injury) for each of three variables: tubular dilatation/flattening, tubular casts, and tubular degeneration/vacuolization. For each animal, 10 cortical high-power fields (HPF) were examined at random. For each variable within each field, a score of 0 was assigned when Ͻ5% of the tubules were affected, a score of 1 when 5 to 33% were affected, a score of 2 when 34 to 66% were affected, and a score of 3 when Ͼ66% were affected. For immunohistochemistry, tissue was immediately frozen in OCT compound at Ϫ20°C. Four-micrometer kidney cryostat sections were fixed with ether/ethanol, incubated with 0.3% H 2 O 2 for 30 min, and blocked with dilute horse serum. Sections were stained for neutrophils by sequential incubation with rat anti-mouse neutrophil (mAb 7/4; Serotec, Raleigh, NC) at 1:60 for 30 min followed by horseradish peroxidase (HRP)-conjugated rabbit anti-rat IgG (Sigma) at 1:60 for 30 min and diaminobenzidine reagent (Vector Labs, Burlingame, CA) for 10 min. A blinded observer counted the number of neutrophils per HPF and recorded the average of 10 fields for each sample. In an analogous manner, sections were stained for intercellular adhesion molecule-1 (ICAM-1) with hamster anti-mouse ICAM-1 (BD Biosciences Pharmingen, San Diego, CA) at 1:20, followed by biotinylated mouse anti-hamster IgG (Pharmingen) at 1:100, and detection via the DAB system (Vector Labs), with hematoxylin counterstain.
Cytokine Measurement
TNF and IL-1␤ levels were determined from sera obtained at baseline and 2 and 6 h after LPS administration using commercially available ELISA kits for mouse TNF and IL-1␤ (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions.
Caspase Enzyme Activity
Frozen whole kidney was homogenized at 4°C using 10 strokes with a glass-Teflon tissue grinder in buffer (50 mM NaCl, 20 mM HEPES [pH 7.2], 10% sucrose, 1 mM EDTA, 10 mM dithiothreitol [DTT], 0.2 mM PMSF, 1 g/ml pepstatin A, and 0.1% CHAPS). Homogenate was centrifuged at 10,000 ϫ g for 15 min at 4°C, and the supernatant was analyzed for caspase-3 and caspase-1 activity using a commercially available kit (Biomol, Plymouth Meeting, PA) according to the manufacturer's instructions, with the following modifications. For each reaction, 20 l of homogenate was added to 70 l of reaction buffer (100 mM NaCl, 50 mM HEPES [pH 7.4], 0.1% CHAPS, 10 mM DTT, 1 mM EDTA, and 10% glycerol). Reactions were initiated by adding 10 l of caspase substrate to each well. For caspase-1 and caspase-3, substrates were 0.05 mM (final concentration) Ac-YVAD-AMC and 0.03 mM Ac-DEVD-AMC, respectively. Reactions were run in a 96-well plate at 37°C for 60 min, with signal measured by fluorometer at an excitation wavelength of 360 nm and emission wavelength of 460 nm. To correct for background signal, the reading from control wells that contained substrate and buffer but no homogenate was subtracted from each reaction. Activity is expressed as mM AMC liberated per min, calculated from an AMC standard curve, normalized to the homogenate protein concentration as determined by the Bradford assay (Biorad).
Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick-End Labeling Staining
Tissue sections were stained for apoptotic nuclei via the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) technique, using a commercially available kit (Trevigen, Gaithersburg, MD), according to the manufacturer's instructions. In brief, formalin-fixed, paraffin-embedded kidneys were cut into 4-M sections and mounted on charged slides. Slides were rehydrated into PBS by washing in a series of graded alcohols. This was followed by proteinase K treatment (20 g/ml) for 30 min at 37°C and incubation in 3% H 2 O 2 /methanol for 5 min. Specimens were incubated with terminal deoxynucleotidyl transferase/Br-dNTP mixture at 37°C for 60 min, followed by anti-BrdU at 1:150 overnight at 4°C. This was followed by incubation in streptavidin-HRP at 1:500 for 30 min and subsequent detection with TACS blue label for 5 min. Sections were counterstained with nuclear fast red for 10 min, washed, dehydrated, and mounted under coverslips. Sections were examined under light microscopy for TUNEL-positive nuclei, and these were counted and assigned to glomerular, vascular, tubular, and peritubular compartments.
Ligase-Mediated-PCR
When the mice were killed, kidneys were cut into thirds and snap-frozen in liquid nitrogen. From this, genomic DNA was purified by means of the DNeasy DNA purification system (Qiagen, Valencia, CA) and quantified spectrophotometrically. The extent of DNA laddering was amplified and detected via ligase-mediated-PCR (LM-PCR) using a commercially available kit (Clontech, Palo Alto, CA) according to the manufacturer's instructions as follows. DNA isolated from each animal was incubated with supplied primer targets and T4 DNA ligase for 18 h at 16°C. Twenty micrograms of this ligated DNA was then used as the template for PCR, using supplied primers and Advantage DNA polymerase (Clontech) for 21 cycles at 94°C (1 min)/72°C (3 min). The reaction product for each animal was electrophoresed through a 1.3% agarose gel, and ethidium bromidestained bands were detected with ultraviolet light illumination. To ensure that an equivalent amount of genomic DNA template was used for each animal, standard PCR for the gene En-2 was performed, using primers contained in the above kit. The intensity of each band was calculated using Labworks 4.0 (Upland, CA) imaging software. A total densitometry score reflecting the amount of apoptosis in each lane was calculated by summing the intensity of each individual band, weighting 200-bp bands as 1.0, 400-bp bands as 0.5, 600-bp as 0.333, and 800-bp band as 0.25, etc., to account for that for a given intensity, smaller molecular weight bands are the product of more frequent DNA cleavage.
Real-Time PCR
A portion of frozen kidney was placed in Trizol reagent (Life Technologies BRL, Grand Island, NY), from which total RNA was purified according to the manufacturer's instructions. To remove all traces of genomic DNA, we then treated samples with RNAse-free RQ1 DNAse (Promega, Madison, WI; 1 U/4 g RNA) in 10 l of reaction buffer (final concentration 40 mM Tris-HCl, 10 mM MgSO 4 , and 1 mM CaCl 2 [pH 8.0]) at 37°C for 30 min. This was followed by addition of 1 l of 20 mM EGTA [pH 8 .0] to stop the reaction, and incubation at 65°C for 10 min to inactivate the DNAse. cDNA was generated from RNA using random hexamers as primers with the SuperScript first-strand synthesis kit (Life Technologies BRL), according to the manufacturer's instructions, and diluted fivefold before analysis.
Real-time PCR was performed using the Prism 7700 reactor and the SybrGreen intercalating dye method with HotStar DNA polymerase (Applied Biosystems, Foster City, CA). Each reaction was conducted in a total volume of 50 l with primers at 200 nM, 1 mM dNTP, 3 mM MgCl 2 , and 10 l of sample or standard cDNA. PCR was carried out with a hot start at 95°C (5 min) followed by 45 cycles at 95°C (15 s)/60°C (30 s). For each sample, the number of cycles required to generate a given threshold signal was recorded. Using a standard curve generated from serial dilutions of kidney cDNA, the ratio of ICAM-1 expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was calculated for each experimental animal and normalized relative to an average of ratios from the control group. Measurements of macrophage inflammatory protein-2 (MIP-2) and TNF mRNA expression were performed in an analogous manner except that the annealing temperature for TNF was 58°C. Products of each reaction yielded a single band when run on agarose gel, confirming specific amplification. Primers were synthesized by Integrated DNA Technologies (Coralville, IA), with sequences as follows: GAPDH forward primer 5'-GGCAAATTCAACGGCACAGT-3', GAPDH reverse primer 5'-AGATGGTGATGGG-CTTCCC-3', TNF forward primer 5'-CCGATGGGTTGTACCTTGTC-3', TNF reverse primer 5'-GTGGGTGAGGAGCACGTAGT-3', ICAM-1 forward primer 5'-CGCAAG-TCCAATTCACACTGA-3', ICAM-1 reverse primer 5'-CAGAGCGGCAG-AGCAAAA G-3', MIP-2 forward primer 5'-CACCAACCACCAGGCTACA-3', and MIP-2 reverse primer 5'-GCCCTTGAGAGTGGCTATGA-3'.
In Situ RNA Hybridization
To localize the expression of MIP-2, in situ hybridization was performed as follows. Ten-micrometer paraffin sections were airdried and rehydrated by incubation with Histoclear and graded alcohol solutions. This was followed by several washes in DEPC-treated water and postfixation for 15 min in 4% paraformaldehyde/0.1 M sodium phosphate. Sections were chemically blocked with sequential 5-min washes in 0.25 and 0.5% (vol/vol) acetic anhydride in 0.1 M TEA buffer, followed by rinsing in 2ϫ SSC, permeabilization with 20 g/ml proteinase K in TE buffer at 37°C for 30 min, and washing with 2 mg/ml glycine in PBS. Sections were then washed in PBS and incubated for 2 h at 32°C in prehybridization buffer (4ϫ SSC, 0.5ϫ Denhardt's solution, 0.2 g/ml dextran sulfate, 50% formamide, 0.25 mg/ml polyA, 0.25 mg/ml ssDNA, 0.25 mg/ml tRNA, and 0.1 M DTT). Sections then were hybridized with digoxin-labeled probe for MIP-2 (antisense sequence 5Ј-GTGGCTATGACTTCTGTCT-GGGCGCAGTGG-3Ј; synthesized by GeneDetect.com, Auckland, New Zealand) at 200 ng/ml in hybridization buffer, overnight at 32°C. Slides then were washed in 1ϫ SSC/10 mM DTT at 52°C for 15 min followed by 0.5ϫ SSC/10 mM DTT at 52°C for 15 min. Sections were washed in TBS, blocked in TBS/0.1% Triton X-100/1% Blocking Reagent (Roche Applied Science, Indianapolis, IN) for 30 min, and incubated in AP-conjugated sheep anti-digoxigenin Fab (Roche) at 1:400 for 4 h. Signal was detected with nitro blue tetrazolium/5-bromo-4-chloro-3-indoyl-phosphate, using a commercially available kit (Roche). Sections were incubated in parallel with sense probe to serve as a control.
Western Blotting
A piece of frozen kidney was thawed, weighed, and homogenized in buffer (PBS [pH 7.4 ] that contained 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 2 mM EDTA, 2 mM EGTA, 0.1% 2-mercaptoethanol, 5 g/ml pepstatin A, 50 g/ml PMSF, and one protease inhibitor tablet [Roche] per 25 ml) at a concentration of 60 mg tissue/ml. Homogenate protein concentration was determined by the BCA method (Pierce Biotechnology, Rockford, IL) for standardization. Samples (50 g protein) were electrophoresed through a 15% SDS-PAGE gel under reducing conditions. Proteins were transferred to an Immobilon-P nitrocellulose membrane (Millipore, Bedford, MA), and blocked overnight in 2% milk/1% BSA/TBST. This membrane was then incubated with goat anti-mouse IL-18 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 followed by HRP rabbit anti-goat IgG (Sigma) at 1:5000, and activity was detected using the Supersignal West Pico chemiluminescent kit (Pierce Biotechnology). Recombinant mouse IL-18 (R&D Systems) was used as a positive control at 3 ng per lane. In an analogous manner, membranes were probed for TNF, using goat anti-mouse TNF (R&D Systems) at 1:1000 followed by HRP anti-goat IgG (Sigma) at 1:2000. Four animals were randomly selected from each group for analysis.
Statistical Analyses
Data were analyzed with Minitab software (State College, PA). Unless noted otherwise, data are given as mean Ϯ SEM. Groups were compared by two-tailed t test, or ANOVA when more than two groups were compared. The Tukey correction for multiple comparisons was used when comparing more than two groups. P Յ 0.05 was considered significant.
Results
LPS Activates Caspases within the Kidney
In comparison with unmanipulated mice, LPS administration caused a 16-fold increase in activity of the principal "executioner" caspase, caspase-3, in the kidney. This increase was significantly attenuated by treatment with the irreversible, cell-permeable, broad-spectrum caspase inhibitor z-VAD (Figure 1A) . Notably, the activity of caspase-1, which does not play a role in apoptosis but instead mediates inflammation via cleaving inflammatory cytokines IL-1 and IL-18 to their active forms (19, 20) , was not increased by LPS treatment ( Figure 1B 
z-VAD Protects against LPS-Induced ARF
LPS injection produces an abrupt rise in BUN and moderate tubular injury, as we have described previously. Treatment with z-VAD provided marked protection against this rise in BUN (24-h values of 115.2 Ϯ 3.3 [n ϭ 7] and 42.6 Ϯ 3.6 mg/dl [n ϭ 8] in the vehicle and z-VAD groups, respectively; P Ͻ 0.001; Figure 2A ). Likewise, serum creatinine levels when the mice were killed were also significantly less in the z-VAD group (0.61 Ϯ 0.07 versus 0.29 Ϯ 0.01 mg/dl; P ϭ 0.005; Figure 2B ), with no difference in the BUN/creatinine ratios between the two groups. Evidence of tubular injury on light microscopy was evident in mice that received LPS plus vehicle but reduced in mice that received z-VAD (cortical injury score 1.2 Ϯ 0.1 and 0.8 Ϯ 0.1 in the vehicle and z-VAD groups, respectively; P ϭ 0.03; Figure 2 , C and D). Thus, caspase inhibition was protective against both the functional and the pathologic renal injury induced by LPS.
We previously described that TNF is a crucial mediator of LPS-induced ARF, acting through its TNFR1 receptor. After LPS injection, serum TNF levels increased dramatically, from Figure 3 . Effect of caspase inhibition on LPS-induced TNF release. Serum TNF was determined by ELISA. At baseline, circulating levels of TNF were barely detectable using a sensitive ELISA technique. Two hours after LPS injection, there was a profound increase in serum TNF, which was unaffected by z-VAD administration. zero at baseline to~3 ng/ml at 2 h, and returned close to baseline by 6 h. However, the serum TNF levels were not affected by z-VAD administration (Figure 3) .
Prevention of LPS-Induced Renal Apoptosis by Caspase Inhibition
As we described previously, LPS injection resulted in apoptosis in the kidney as detected by TUNEL staining (Figure 4 ), in comparison with the scarce amount of apoptosis in kidney at baseline. Apoptotic nuclei were most frequently observed in renal cortex, present in roughly equal numbers in renal tubular cells, arterioles, and peritubular areas, which could represent peritubular capillaries. However, mice that received z-VAD treatment had significantly fewer apoptotic nuclei (Table 1) . These results were confirmed with LM-PCR, which again demonstrated significantly less apoptosis in mice that received z-VAD in comparison with mice that received LPS plus vehicle (densitometry score 147 Ϯ 48 versus 392 Ϯ 74; P ϭ 0.02), as was expected of caspase inhibition ( Figure 5 ). 
Prevention of LPS-Induced Renal Inflammation
LPS administration causes a robust expression of various chemotactic chemokines and adhesion molecules in a variety of organs, including the kidney (16, 21, 22) . Consistent with this, we have described diffuse infiltration of the renal parenchyma with neutrophils in association with LPS-induced ARF (3). Surprising is that caspase inhibition significantly reduced this renal neutrophil infiltration (7.6 Ϯ 0.7 versus 2.6 Ϯ 0.4 PMN/HPF in vehicle-treated and z-VAD-treated groups, respectively; P Ͻ 0.001; Figure 6 ). To gain further insight into this anti-inflammatory activity of caspase inhibition, we used real-time PCR to examine the expression of adhesion molecule ICAM-1 and chemokine MIP-2 (or CXCL2), which is chemotactic for neutrophils. As depicted in Figure 7 , LPS caused a profound increase in the expression of both ICAM-1 and MIP-2, which was significantly abrogated by caspase inhibition. Immunohistochemistry localized this LPS-induced ICAM-1 expression to renal arterioles ( Figure 8, A and B) , and in situ hybridization localized MIP-2 RNA expression to scattered tubular and peritubular cells (Figure 8 ), a pattern similar to the distribution of TUNEL-positive nuclei. In contrast, although LPS administration caused upregulation of TNF within the kidney, this was not significantly affected by caspase inhibition as determined by either real-time PCR (Figure 7) or Western blot (data not shown).
Caspase-1 is not involved in executing apoptosis but does have an important role in inflammation by cleaving precursors of inflammatory mediators IL-1 and IL-18 to their active forms (19, 23) . Caspase-1-mediated activation of IL-18 has been shown to be a key event in ischemia-reperfusion-induced ARF (20). Thus, we wondered whether the anti-inflammatory effect of z-VAD was occurring via inhibition of caspase-1. However, as noted above, caspase-1 activity was not increased by LPS. As expected, LPS caused a substantial increase in serum IL-1, from zero at baseline to~400 pg/ml at its peak 6 h later. However, this was not significantly affected by z-VAD treatment ( Figure 9A ). In addition, Western blotting of renal homogenates showed that after LPS treatment, all IL-18 reactivity remained confined to the inactive 24-kD precursor ( Figure  9B ).
Discussion
The pathophysiology of LPS-induced ARF is incompletely understood. The early release of TNF into the circulation that follows LPS administration has been shown to be a key early mediator (3, 4) , but subsequent events in the kidney have not been investigated in detail. Whereas LPS has well-known hemodynamic effects, Knotek et al. (4) showed that LPSinduced ARF occurs at relatively low doses of LPS that do not produce significant hypotension. Other work has suggested that LPS causes damage to various organs, including the kidney, by inducing infiltration with neutrophils and other inflammatory cells (17, 22, 24, 25) . In the experiments described herein, we tested the hypothesis that LPS-induced ARF is mediated through caspase activation and apoptosis. The dramatic protection against LPS-induced ARF that we observed by using a pharmacologic caspase inhibitor is proof that this pathway is a crucial mediator of LPS-induced ARF. More surprising, the reduction in infiltrating neutrophils and other inflammatory markers seen with caspase inhibition suggests a strong link between the processes of apoptosis and inflammation.
Apoptosis within the kidney has been clearly demonstrated in animal models of renal ischemia-reperfusion injury (26, 27) , and pharmacologic caspase inhibitors have been shown to protect against the decline in GFR (28) . However, until this report, caspase inhibition has not been previously examined in a model of LPS-induced ARF. Although ischemia-reperfusion and LPS both cause an abrupt decline in GFR, the two models are pathologically distinct. Ischemia-reperfusion injury is characterized by widespread tubular necrosis (5), whereas the more modest tubular injury observed in LPS-induced ARF more closely resembles the pathology of human ARF (29, 30) . In renal ischemia-reperfusion injury, caspase inhibition was shown to exert its protective effect primarily by inhibiting caspase-1-mediated activation of inflammatory cytokine . In contrast, we found no activation of caspase-1 or IL-18 resulting from LPS administration.
LPS has been previously shown to lead to apoptosis of a variety of cells types, especially the endothelium (31) (32) (33) (34) , in models of sepsis and yet is also known to prevent apoptosis in macrophages and neutrophils (35) . We observed apoptosis in both tubular and vascular structures, in contrast to the predominantly tubular location of apoptotic debris described in ischemia-reperfusion (36) . Apoptotic death of renal endothelial cells could conceivably lead to a decline in GFR by causing changes in renal vascular tone or by exposing procoagulant subendothelial surfaces (37, 38) . Loss of tubular cells by either necrotic or apoptotic death could lead to a decline in GFR by causing tubular backleak, by increasing tubuloglomerular feedback, or via cast formation (39) . Although the absolute number of apoptotic cells that we observed in a given field was relatively low, apoptosis occurs continually after LPS injection (3), and apoptotic cells are cleared rapidly (40) . Hence, sections that were obtained when the mice were killed represent only a "snapshot" of the extent of apoptotic death occurring at that time. Thus, over time, there is likely to be a sizable amount of apoptosis in this LPS-induced ARF model.
The relevance of apoptosis within the kidney in human ARF has yet to be confirmed. Hotchkiss et al. (41) reported evidence of increased apoptosis at autopsy in people who died of septic shock, primarily in splenic lymphocytes and intestinal epithelial cells. Evidence of apoptosis occurring in the kidney was not clearly observed, but the primary technique used to detect apoptosis in this study was light microscopy, which is relatively insensitive. Endothelial cell apoptosis may be difficult to detect, as injured endothelial cells quickly detach into the bloodstream and are cleared (42) . Our data clearly show that apoptosis occurs in mouse kidney after LPS administration, but the degree may diminish with time (3), which could also account for why little renal apoptosis was seen in the humans autopsied days to weeks after the onset of septic shock. Nevertheless, caution should be used when extrapolating results of animal studies to humans.
There are several possible mechanisms by which LPS could induce caspase activation and apoptosis. Caspase-8 is activated by the ligation of cell surface receptors TNFR1 and Fas by their respective ligands. Given the essential role of TNF in LPS-induced renal failure (3, 4) and that TNFR1-deficient mice had markedly less apoptosis in kidney after LPS administration (3), this pathway is a likely possibility. LPS is also known to increase expression of both Fas and Fas ligand within the kidney, although Fas-deficient mice are not protected against LPS-induced ARF (3). However, the mitochondrial pathway of apoptosis, which begins when release of cytochrome c activates caspase-9, is triggered by various events that may be present in the kidney after exposure to LPS, such as the presence of hypoxia or reactive oxygen species, or removal of extracellular survival factors. Both the receptor-mediated and mitochondrial pathways of caspase activation converge on a common pathway that includes activation of caspase-3, which bring about the actual phenotypic changes associated with apoptosis. z-VAD, which we used in these experiments, is a broad-spectrum inhibitor of caspases and does not allow us to determine the extent to which each pathway contributes. To add further to this complexity, LPS is also known to induce several so-called inhibitor of apoptosis proteins, which likely interact with the above pathways (43) . Thus, deciphering the mechanism of LPS-induced renal apoptosis requires further study.
Apoptosis is classically described as a noninflammatory process, with apoptotic cells being phagocytosed efficiently by neighboring cells (44) . The reduction in renal inflammation that we noted with caspase inhibition was therefore unexpected. In fact, apoptosis of neutrophils has a well-documented role in resolution of inflammation; thus, in theory, inhibition of apoptosis would have a proinflammatory effect (45, 46) . Although caspase-1 contributes to inflammation by activating IL-1 and IL-18, we found no evidence for involvement of this pathway in LPS-induced renal inflammation. Work by Daemen et al. (28) showed a similar improvement in renal neutrophil infiltration when caspase inhibitors protected against ischemiareperfusion-induced ARF, which was attributed to inhibiting the release of the inflammatory cytokine endothelial monocyteactivating polypeptide-II from apoptotic renal tubular cells. Schaub et al. (47) showed evidence supporting a role for endothelial cell apoptosis in causing vascular inflammation in a rat model of atherosclerosis, implicating chemokines such as the neutrophil chemoattractant IL-8 as responsible for attracting inflammatory cells to the vascular wall. Here we have shown that the LPS-induced upregulation in chemokines such as MIP-2, the mouse analogue of rat and human IL-8, was decreased by caspase inhibition, suggesting that cells within the kidney may produce this inflammatory mediator in the process of undergoing apoptosis and thereby increase LPSinduced inflammation. Caspase activation has also been described in tubular cell necrosis (48) , and it is possible that caspase activation in necrotic or viable cells contributes to renal inflammation as well. The resultant infiltration of the kidney with neutrophils, also prevented by caspase inhibition, may have both an adaptive role in removing apoptotic debris and a maladaptive role in causing injury to the renal parenchyma. A variety of other links between apoptosis and inflammation have begun to emerge in the literature (49 -53) . The exact manner in which caspase activation leads to renal inflammation requires further study, but that renal expression of the upstream inflammatory mediator TNF was unaffected by caspase inhibition suggests that this effect is not promiscuous.
In summary, we have proven a key role for the caspase cascade in mediating the pathologic and functional changes seen in LPS-induced ARF. Caspase activation may lead to LPS-induced ARF not only by inducing apoptotic cell death but also by causing renal inflammation. A recent review identified Ͼ280 different substrates of caspase cleavage, including proteins with important roles in cell structure, signaling, transcription, and intercellular adhesion (54) . Thus, caspases may prove to be key mediators of injury and inflammation through multiple mechanisms and may ultimately prove to be important therapeutic targets in sepsis-induced ARF. Figure 9 . Caspase inhibition does not effect IL-1 or IL-18 activation. Serum IL-1 levels, as determined by ELISA, and renal IL-18 expression, as determined by Western blot of kidney homogenate, are shown. LPS administration caused a strong increase in circulating IL-1, but this was not significantly altered by z-VAD (A). LPS administration increased the amount of the inactive 24-kD precursor of IL-18 compared with baseline (B). However, the active 18-kD form, which results from caspase-1 cleavage of the precursor, was not detected either at baseline or after LPS administration, regardless of z-VAD treatment. Recombinant IL-18, whose sequence is identical to the active 18-kD form, was used as a control. Normal spleen is shown as a positive control for the 24-kD precursor.
